Paper Details

  1. Home
  2. Paper Details

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Author: ArvisCatherine Dubos, BoyerMichael, HirshVera, KimDong-Wan, KimMiyoung, KimSang-We, KölbeckKarl, LaskinJanessa, LaurieScott A, LeeKi Hyeong, LuShun, MasseyDan, MokTony, O'ByrneKen, ParkKeunchil, Paz-AresLuis, ShahidiMehdi, ShiYuankai, TanEng-Huat, TsaiChun-Ming, YangJames Chih-Hsin, ZazulinaVictoria, ZhangLi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This international, randomized, open-label phase 2B trial compared afatinib and gefitinib in treatment-naive patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Afatinib was found to significantly improve progression-free survival and time-to-treatment failure compared to gefitinib, with manageable side effects.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and gefitinib in this sett...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(16)30033-X

データ提供：米国国立医学図書館（NLM）

Treating EGFR Mutation-Positive Lung Cancer: A Race Between Two Therapies

The battle against non-small-cell lung cancer (NSCLC), a formidable foe, is an ongoing challenge for healthcare providers. This research delves into the world of EGFR mutation-positive NSCLC, a specific subtype of this disease, and compares the efficacy of two targeted therapies: afatinib and gefitinib. Think of this research as a race across a vast desert, each therapy representing a different camel, competing for the best route to victory against this devastating disease.

The authors conducted a phase 2B, randomized controlled trial to compare afatinib and gefitinib in treatment-naive patients with EGFR mutation-positive NSCLC. The results showed that afatinib was associated with a significantly longer progression-free survival and time-to-treatment failure than gefitinib. This is like one camel outperforming the other in a race, reaching the oasis of longer survival and better treatment outcomes.

A New Frontier in Targeted Therapy: Finding the Optimal Weapon

The study suggests that afatinib may be a more effective treatment option for treatment-naive patients with EGFR mutation-positive NSCLC compared to gefitinib. This is a significant finding, as it provides valuable insights into the potential of targeted therapies in treating this disease. This is like discovering that one camel is better equipped for the challenges of the desert, possessing a unique set of skills and adaptations that give it a competitive edge.

Dr. Camel's Conclusion

This research underscores the importance of tailoring treatment strategies to the specific needs of each patient. The findings suggest that afatinib may be a more effective treatment option for patients with EGFR mutation-positive NSCLC, but it is essential to consider the potential side effects of each therapy and make informed decisions in consultation with a healthcare professional. This research serves as a valuable guidepost for future explorations in the field of targeted therapy for lung cancer.

Date :
  1. Date Completed 2017-06-13
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

27083334

DOI: Digital Object Identifier

10.1016/S1470-2045(16)30033-X

Related Literature

Article Analysis
・Side Effects of afatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.